ANTIHYPERLIPIDEMIC DRUGS MARKET ANALYSIS

The global antihyperlipidemic drugs market was valued at US$ 12.6 Bn in 2022 and is forecast to reach a value of US$ 22.5 Bn by 2030 at a CAGR of 7.5% between 2023 and 2030. The global antihyperlipidemic drugs market is experiencing strong growth due to the rise in prevalence of hyperlipidemia and surge in sedentary lifestyle across the world. Moreover, increasing demand for antihyperlipidemic drugs and growing geriatric population across the globe is expected to boost the growth of the market. However, factors such as high cost of treatment and lack of awareness among people are expected to hamper the market growth.

Global Antihyperlipidemic Drugs Market: Regional Insights

Based on geography, the global antihyperlipidemic drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, North America is expected to gain highest share in the market during the forecast period due to the rise in prevalence of hyperlipidemia, increasing consumer awareness about the risk of cardiovascular disease, surge in sedentary lifestyle, and high demand for antihyperlipidemic drugs in this region. For instance, hyperlipidemia (high cholesterol) can increase the risk of heart attack and stroke. According to the American Stroke Association, stroke is the No. 5 cause of death and a leading cause of disability in the United States. Every year, more than 795,000 people in the U.S. have a stroke. About 610,000 of these are first or new strokes.

Europe and Asia Pacific are also expected to witness robust growth in the antihyperlipidemic drugs market owing to the increasing burden of hyperlipidemia, growing geriatric population, increasing awareness about the risk of cardiovascular diseases, and increasing demand for antihyperlipidemic drugs. For instance, according to the repost by AHA Journals, in the European Union (EU), stroke is the most common cause of death and a leading cause of adult disability. The Stroke Action Plan for Europe (SAP-E) is a pan-European project that sets targets for the implementation of evidence-based preventive actions and stroke services until 2030.

Figure 1. Global Antihyperlipidemic Drugs Market Share (%), by Region, 2023

To learn more about this report, request sample copy

Global Antihyperlipidemic Drugs Market Drivers:

Rise in prevalence of hyperlipidemia to augment market growth

One of the key factors expected to augment growth of the global antihyperlipidemic drugs market during the forecast period is the rise in prevalence of hyperlipidemia across the world. For instance, hyperlipidemia defines an elevated level of lipids, like cholesterol and triglycerides, in the blood, which in turn increases the risk of heart disease and stroke, the leading cause of death worldwide. According to the World Heart Federation, high cholesterol causes 5 Billion deaths each year across the globe. It is a major a risk factor for heart disease and stroke in low- and high- income countries. A healthy diet, regular exercise, and medication can help reduce high cholesterol.

Surge in sedentary lifestyle to underpin market growth

Another factor driving the growth of the global antihyperlipidemic drugs market is the increase in sedentary lifestyle. For instance, drinking a lot of alcohol, smoking, eating foods that have a lot of saturated or trans fats, and being overweight may increase the cholesterol level (hyperlipidemia). The Centers for Disease Control and Prevention (CDC) found that 25.3% of all American adults are physically inactive. Moreover, around 1 to 2 Billion deaths per year are attributed to physical inactivity, prompt World Health Organization (WHO) to issue a warning that a sedentary lifestyle could very well be among the leading causes of death and disability in the world.  

Global Antihyperlipidemic Drugs Market Opportunities:

Increasing demand for antihyperlipidemic drugs across the globe is expected to provide significant growth opportunities for players in the antihyperlipidemic drugs market. For instance, with the rise in burden of hyperlipidemia and cardiovascular disease, the demand for antihyperlipidemic drugs is also increasing. They are also known as lipid-lowering agents; provide safe/effective treatment for hyperlipidemia (increase in lipid level in the blood). In December 2021, the U.S. Food & Drug Administration (FDA) approved Novartis’s Leqvio (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol.

Growing geriatric population is expected to offer lucrative growth opportunities for players in the antihyperlipidemic drugs market. For instance, total and LDL (low-density lipoprotein) cholesterol levels increase with age, as does the incidence of cardiovascular disease. Aging can cause changes in the heart and blood vessels that may increase the risk of cardiovascular disease. People age 65 and older are more likely than younger people to suffer from cardiovascular disease. According to the WHO, by 2030, 1 in 6 people in the world will be aged 60 years or over, by 2050, the world’s population of people aged 60 years and older will double (2.1 billion).

Global Antihyperlipidemic Drugs Market Trends:

High demand statin hyperlipidemia drugs is a recent trend

Statins (HMG CoA reductase inhibitors) are prescription medicines that people take to bring their cholesterol down to normal levels. Statins also are safe and effective in reducing triglyceride levels in patients with hypertriglyceridemia. It is the first line of therapy that reduces the risk associated with heart attacks which in turn contributes to the market growth. Systematic review of 75 clinical trials found that rosuvastatin and atorvastatin statins lowered LDL cholesterol by more than 40% (high-intensity statins). This trend is expected to continue over the forecast period.

Increase in awareness among people is another trend

With the increasing awareness among people about the risk of hyperlipidemia and cardiovascular disease, the demand for antihyperlipidemic drugs is also increasing. Hyperlipidemia is one of the important modifiable risk factors for CVDs. Raising public awareness of CVD risks is an important step in reducing CVD burdens. Thus, several healthcare organizations and governments across the globe are increasing public awareness and knowledge about cholesterol and its management. This trend is also expected to continue over the forecast period.

Global Antihyperlipidemic Drugs Market Restraints:

High cost of treatment to hinder growth of the market

One of the key factors expected to hamper growth of the global antihyperlipidemic drugs market is the high cost of treatment. For instance, statins are a type of medication prescribed to treat high cholesterol by lowering cholesterol production in the liver. The average retail cost of statins used to treat moderate cases of high cholesterol is US$ 139.29 for generic medications and US$ 360.43 for brand-name statins. Without insurance and discount codes, statins can vary from about US$ 33 per month to US$ 600 per month. These drugs will probably cost more if a person needs a higher dosage, restraining the growth of the market.

Lack of awareness to hamper the growth of the market

Another factor which is hampering the growth of the antihyperlipidemic drugs market is the lack of awareness about the risk of hyperlipidemia and cardiovascular diseases. Hyperlipidemia is one of the important modifiable risk factors for cardiovascular diseases (CVDs), and increasing public awareness of CVD risks is an important step in reducing CVD burdens. Lack of awareness among people hampers the use or the adoption of antihyperlipidemic drugs. However, with the increasing awareness among people about the risk of hyperlipidemia and cardiovascular disease, the demand for antihyperlipidemic drugs is also increasing.

Figure 2. Global Antihyperlipidemic Drugs Market Share (%), by Drug Class, 2023

To learn more about this report, request sample copy

Global Antihyperlipidemic Drugs Market Segmentation:

The global antihyperlipidemic drugs market report is segmented into Drug Class and Region.

Based on Drug Class, the market is segmented into Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, PCSK9 Inhibitors, Combination, and Others. Out of which, Statins Segment is expected to dominate the antihyperlipidemic drugs market over the forecast period and this is attributed to the increasing demand for statin hyperlipidemia drugs.

Bile Acid Sequestrants Segment is also expected to witness significant growth in the near future and this is due to the increasing demand for bile acid sequestrants. Bile acid sequestrants are drugs that help lower LDL (bad) cholesterol.

Global Antihyperlipidemic Drugs Market: Key Developments

In May 2022, Zydus Lifesciences announced the launch of its Bempedoic acid drug in India under the Bemdac brand for the treatment of uncontrolled levels of bad cholesterol.

In November 2021, Pfizer announced top line results from the Phase 2b study of vupanorsen (PF-07285557), an investigational therapy being developed for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG). The study showed that vupanorsen achieved a statistically significant lowering of non- HDL-C, triglycerides, and other lipoproteins related to cardiovascular disease.

In April 2021, the Food and Drug Administration (FDA) approved Praluent (alirocumab) injection for adult patients with homozygous familial hypercholesterolemia (HoFH), a genetic condition that causes severely high cholesterol.

Global Antihyperlipidemic Drugs Market: Key Companies Insights

The global antihyperlipidemic drugs market is highly competitive. This is attributed to the increase in prevalence of hyperlipidemia across the world, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global antihyperlipidemic drugs market are Sanofi S.A., Pfizer Inc., Mylan N.V, Amgen Inc., Abbvie Inc., Merck & Co., Inc., Dr. Reddy’s Laboratories Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, and Daiichi Sankyo Company, Limited, among others.

*Definition: Hyperlipidemia is a term that encompasses various genetic and acquired disorders that describe elevated lipid levels within the body. It is a very common disorder, and thus, there is an increasing demand for antihyperlipidemic drugs worldwide.